Novartis (NYSE:NVS) Shares Unloaded Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently sold shares of Novartis AG (NYSE:NVS). In a filing disclosed on October 22nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Novartis stock on September 25th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of FMC (NYSE:FMC) on 9/25/2025.
• Sold $1,001 – $15,000 in shares of Merit Medical Systems (NASDAQ:MMSI) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of Darden Restaurants (NYSE:DRI) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of Kenvue (NYSE:KVUE) on 9/25/2025.
• Sold $1,001 – $15,000 in shares of Beacon Financial (NYSE:BBT) on 9/25/2025.
• Sold $1,001 – $15,000 in shares of British American Tobacco (NYSE:BTI) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of Rollins (NYSE:ROL) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of SAP (NYSE:SAP) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of MGP Ingredients (NASDAQ:MGPI) on 9/25/2025.

Novartis Trading Up 0.1%

Shares of Novartis stock opened at $131.60 on Friday. Novartis AG has a 12-month low of $96.06 and a 12-month high of $133.55. The company has a market cap of $277.99 billion, a price-to-earnings ratio of 19.16, a PEG ratio of 1.84 and a beta of 0.64. The company has a current ratio of 0.82, a quick ratio of 0.62 and a debt-to-equity ratio of 0.53. The company’s 50-day moving average price is $127.43 and its 200-day moving average price is $119.17.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Harrell Investment Partners LLC grew its position in Novartis by 4.8% during the third quarter. Harrell Investment Partners LLC now owns 6,583 shares of the company’s stock valued at $844,000 after acquiring an additional 304 shares during the last quarter. Argonautica Private Wealth Management Inc. grew its position in Novartis by 3.2% during the third quarter. Argonautica Private Wealth Management Inc. now owns 4,095 shares of the company’s stock valued at $525,000 after acquiring an additional 126 shares during the last quarter. Invested Advisors bought a new position in Novartis during the third quarter valued at approximately $493,000. Cardinal Capital Management grew its position in Novartis by 1.1% during the third quarter. Cardinal Capital Management now owns 49,561 shares of the company’s stock valued at $6,356,000 after acquiring an additional 548 shares during the last quarter. Finally, Spectrum Asset Management Inc. NB CA grew its position in Novartis by 6.1% during the third quarter. Spectrum Asset Management Inc. NB CA now owns 26,168 shares of the company’s stock valued at $3,356,000 after acquiring an additional 1,513 shares during the last quarter. 13.12% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. The Goldman Sachs Group restated a “sell” rating and issued a $118.00 price objective (down from $119.00) on shares of Novartis in a research report on Friday, September 12th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Novartis in a research report on Thursday, August 21st. Wall Street Zen upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. Morgan Stanley upgraded shares of Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price objective on the stock in a research report on Friday, August 8th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Novartis has an average rating of “Hold” and an average target price of $120.33.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.